The Nitric Oxide System in Patients with Chronic Heart Failure
The aim of this study was to evaluate the metabolic features of nitric oxide (NO) in patients with chronic heart failure (CHF) of ischemic origin. The study included 303 patients with ischemic CHF who received the standard treatment for CHF. Evaluation of the functional status of the NO system inclu...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
International Medical Research and Development Corporation
2013-09-01
|
| Series: | International Journal of Biomedicine |
| Subjects: | |
| Online Access: | http://ijbm.org/articles/Article3_3_CR6.pdf |
| Summary: | The aim of this study was to evaluate the metabolic features of nitric oxide (NO) in patients with chronic heart failure (CHF) of ischemic origin. The study included 303 patients with ischemic CHF who received the standard treatment for CHF. Evaluation of the functional status of the NO system included the detection of arginine concentrations in the peripheral blood, stable metabolites of nitric oxide (NO2/NO3) and endothelial NO synthase (eNOS) activity. After the initial assessment, patients were randomly divided into groups: the T-group who had torasemide (5-10 mg /day) included in the treatment scheme and the F-group with furosemide (20-40 mg/day). The diuretic dose was titrated according to the severity of the edema syndrome. In the randomly formed A-group of patients, L-arginine hydrochloride (Tivortin, URiA-PHARM, Ukraine) was administered in the treatment scheme for three months. The Tivortin dose was 6 g per day (10 mg syrup three times a day). The presence of diuretics in the treatment scheme allowed for normalizing the functioning of the NO system including eNOS activity. The additional use of L-arginine hydrochloride positively affected the NO metabolism. |
|---|---|
| ISSN: | 2158-0510 2158-0529 |